|
US2020109182A1
|
|
Glp-1 analog fusion protein and preparation method and application thereof
|
|
CN108872207A
|
|
A kind of vitro detection tool and method for evaluating RANKL target spot compound biological activity
|
|
CN107536841A
|
|
Ligustrum lucidum Ait, Rhoifolin, Hyperoside composition and application thereof
|
|
CN107569506A
|
|
Ligustrum lucidum Ait, Rhoifolin composition and application thereof
|
|
CN107536842A
|
|
Ligustrum lucidum Ait, Hyperoside composition and application thereof
|
|
CN109420159A
|
|
A kind of novel stabilising preparation of recombinant protein medicine
|
|
CN108210890A
|
|
The novel stabilising preparation of recombinant human glucagon-like peptide-1 analog fusion
|
|
CN107661288A
|
|
Stable liquid preparation and its preparation containing the analog fusions of GLP 1
|
|
CN107537036A
|
|
A kind of pharmaceutical preparation of human vessel endothelium growth factor resisting monoclonal antibody and its application
|
|
CN103408669A
|
|
Fusion protein of GLP-1 analogue and preparation method and application thereof
|
|
CN103255238A
|
|
Method for controlling generation of mammalian cell lactic acid
|
|
CN101812438A
|
|
Arginine deiminase mutant and preparation and application thereof
|
|
CN101824091A
|
|
G-CSF (Granulocyte-Colony Stimulating Factor) fusion protein mutant, preparation method and application thereof
|
